Browsing
     by title


0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

or enter first few letters:   
OK
Full Text
See detailMélanges mathématiques (Tome troisième)
Catalan, Eugène ULg

in Mémoires de la Societe Royale des Sciences de Liège (1888), 15

Detailed reference viewed: 6 (0 ULg)
Full Text
See detailMélanges offerts à Jean Bobon à l'occasion de la fin de sa carrière professorale
Mormont, Christian ULg; Bobon, Daniel; Croufer, Francis

in Acta Psychiatrica Belgica (1983), 2 et 3

Detailed reference viewed: 31 (2 ULg)
See detailMélanges Philippe Minguet
Duchesne, Jean-Patrick ULg; Durand, Pascal ULg; Steinmetz, Rudy ULg

Book published by Art&Fact (1999)

Detailed reference viewed: 79 (8 ULg)
Peer Reviewed
See detailMélanges Philippe Minguet
Duchesne, Jean-Patrick ULg

in Art&fact (1999), 18

Detailed reference viewed: 52 (4 ULg)
Peer Reviewed
See detailMélanges Pierre Colman
Duchesne, Jean-Patrick ULg

in Art&fact (1996), 15

Detailed reference viewed: 68 (4 ULg)
Full Text
Peer Reviewed
See detailMelanin-concentrating hormone and immune function
Lakaye, Bernard ULg; Coumans, Bernard ULg; Harray, Sophie ULg et al

in Peptides (2009), 30

To date,melanin-concentrating hormone (MCH) has been generally considered as peptide acting almost exclusively in the central nervous system. In the present paper, we revise the experimental evidence ... [more ▼]

To date,melanin-concentrating hormone (MCH) has been generally considered as peptide acting almost exclusively in the central nervous system. In the present paper, we revise the experimental evidence, demonstrating that MCH and its receptors are expressed by cells of the immune system and directly influence the response of these cells in some circumstances. This therefore supports the idea that, as with other peptides, MCH could be considered as a modulator of the immune system. Moreover, we suggest that this could have important implications in several immune-mediated disorders and affirm that there is a clear need for further investigation [less ▲]

Detailed reference viewed: 34 (8 ULg)
Full Text
Peer Reviewed
See detailMelanin-concentrating hormone regulates beat frequency of ependymal cilia and ventricular volume
Conductier, G; Brau, F; Viola, A et al

in Nature Neuroscience (2013), 16

Detailed reference viewed: 23 (2 ULg)
See detailMélanodermie infraclinique et cancers photo-induits
QUATRESOOZ, Pascale ULg; PIERARD-FRANCHIMONT, Claudine ULg; HENRY, Frédérique ULg et al

in Actualités en Ingéniérie Cutanée (2006)

Detailed reference viewed: 22 (1 ULg)
Full Text
Peer Reviewed
See detailLa melanogenese, expression de la differenciation de cellules cancereuses en culture
Bassleer, Roger; De Pauw-Gillet, Marie-Claire ULg; Giet, Didier ULg et al

in Bulletin de l'Association des Anatomistes (1982), 66(194), 291-295

In B16 mouse melanoma in culture, differentiated cells actively synthesize melanin. They are analyzed by cytological and cytochemical methods. When cultured for long periods (several months ... [more ▼]

In B16 mouse melanoma in culture, differentiated cells actively synthesize melanin. They are analyzed by cytological and cytochemical methods. When cultured for long periods (several months), melanogenesis is expressed according to a cyclic way, even when maintained in a culture medium of constant composition and without adding any chemical agent eventually able to influence this phenomenon. The spontaneous cyclic activity is analyseed and an explanation is given as an hypothesis. [less ▲]

Detailed reference viewed: 29 (7 ULg)
See detailMelanoma AntiGEn D2 (MAGED2) a new partner of the DNA damage response?
Pirlot, Céline ULg; Piette, Jacques ULg; Habraken, Yvette ULg

Poster (2014, January)

MAGED2 belongs to the Melanoma AntiGEn (MAGE) family of proteins. It is ubiquitously expressed and its overexpression in many cancers could make it a potential biomarker of tumor development and ... [more ▼]

MAGED2 belongs to the Melanoma AntiGEn (MAGE) family of proteins. It is ubiquitously expressed and its overexpression in many cancers could make it a potential biomarker of tumor development and metastasis formation. Actually, the only known function of this protein is its involvement in the p53 pathways. Indeed, MAGED2 could be a negative regulator of p53 and it increases apoptosis induced by TRAIL in a p53 dependent manner. Moreover, a phosphoproteomic experiment has shown that this protein is likely phosphorylated by ATM, ATR or DNA-PK after exposition to ionizing irradiation. These three kinases are implicated in the DNA damage response (DDR). Our lab showed by yeast two hybrids an interaction between MAGED2 and ATM. Thus, the aims of the project are to confirm and to find the function of this interaction in a DDR context. Current avenues of investigations include determining the impact of MAGED2 depletion and overexpression in the p53, NF-kappaB and cell cycle regulation following double strand break induced by etoposide treatment. Though this study we plan to confirm a new partner of ATM in the DDR pathway, which could be targeted to limit cancer progression and improve the chemotherapy relying on DNA damaging compounds. [less ▲]

Detailed reference viewed: 66 (4 ULg)
See detailMelanoma antigen D2, a substrate of ATM, is a nucleolar protein that shuttles with cell cycle and cellular stress.
Pirlot, Céline; Thiry, Marc ULg; Trussart, Charlotte ULg et al

Poster (2015, November 03)

ATM coordinates numerous facets of the highly regulated DDR network. In order to identify new ATM substrates we have performed a yeast two hybrid experiment with HEAT domains of ATM and an HeLa cDNA ... [more ▼]

ATM coordinates numerous facets of the highly regulated DDR network. In order to identify new ATM substrates we have performed a yeast two hybrid experiment with HEAT domains of ATM and an HeLa cDNA library. Melanoma antigen D2 (MAGED2) was one of the interacting proteins identified in this screen. MAGED2 belongs to the type II Melanoma AntiGEn (MAGE) family. MAGE homology domain, shared by all MAGE proteins, was shown to enhance E3 ligase activity. Actually, little is known about MAGED2 functions. Like every type II MAGE protein, it is expressed in all adult tissues. However, MAGE-D2 has the particularity to be over-expressed in numerous primary cancer and metastasis and it is now recognized as a tumour marker. This over-expression suggests that MAGED2 could be important for the process of cancerisation. MAGED2 was also shown to be a negative regulator of p53, but we did not confirm this property. Proteomic analyses also detected numerous phosphorylated or acetylated residues in response to stress and during cell cycle progression, suggesting a role in cellular signal transduction. We identified the residues targeted by ATM in MAGE-D2 and analysed the localisation of MAGED2 during the interphase and after genotoxic/nucleolar stresses. [less ▲]

Detailed reference viewed: 11 (0 ULg)
Full Text
Peer Reviewed
See detailMelanoma antigen-D2: a nucleolar protein undergoing delocalization during cell cycle and after cellular stress
Pirlot, Céline ULg; Thiry, Marc ULg; Trussart, Charlotte ULg et al

in BBA Molecular Cell Research (2016), 1853(3), 581-595

Detailed reference viewed: 16 (5 ULg)
Full Text
Peer Reviewed
See detailMelanoma screening: results of the first one-day campaign in Belgium (‘Melanoma Monday’)
Vandaele, M.; Richert, Bertrand ULg; Van der Endt, J. M. et al

in Journal of the European Academy of Dermatology & Venereology (2000), 14

Background: Although the incidence of melanoma is increasing and many informative campaigns have been organized. The general population is still little informed about this tumour. Aims: To organize a ... [more ▼]

Background: Although the incidence of melanoma is increasing and many informative campaigns have been organized. The general population is still little informed about this tumour. Aims: To organize a media campaign, with more relevant information and the opportunity for free skin inspections. Methods: A ‘Task Force’ organized a media campaign in April 1999 and convinced 65% of the Belgian dermatologists to give up 4 h of their time to do free skin examinations for skin cancer on Monday 26 April 1999; it was called ‘Melanoma Monday’. Results: A total 2767 patients were screened. We found 25 melanomas and suspected 59 basal cell carcinomas. In the following 4 weeks another 141 melanomas were found. These 166 melanomas found in one month represent 15 –20% of the total number of melanomas per year in Belgium. Summary: A media campaign with relevant information combined with screening opportunities can lead to the early detection of melanomas in a large number of patients and can continue to alert people at risk in the following weeks. [less ▲]

Detailed reference viewed: 9 (2 ULg)
Peer Reviewed
See detailLe mélanome B16 de la souris en culture à trois dimensions
De Pauw-Gillet, Marie-Claire ULg; Christiane, Y.; Foidart, Jean-Michel ULg et al

in Bulletin de l'Association des Anatomistes (1986), 70(210), 21-4

Multicellular spheroids composed of mouse B16 melanoma cells have been prepared in non agitated culture on solid agar. Cells present frequent contacts and an extracellular matrix appears during ... [more ▼]

Multicellular spheroids composed of mouse B16 melanoma cells have been prepared in non agitated culture on solid agar. Cells present frequent contacts and an extracellular matrix appears during cultivation (up to 2 months in agitated suspension); it contains laminin, fibronectin and collagen I, III and IV. Cellular differentiation takes place inside these spheroids (melanogenesis progressively increases), but a relatively intense cell proliferation rate is also maintained. [less ▲]

Detailed reference viewed: 124 (7 ULg)
Full Text
Peer Reviewed
See detailLe mélanome cutané dans une perspective liégeoise. Actualisation de son épidémiologie et avancées diagnostiques.
Quatresooz, Pascale ULg; Hustinx, Roland ULg; Franchimont, Claudine ULg et al

in Revue Médicale de Liège (2007), 62(Supplément), 52-55

Cutaneous melanoma is one of the research poles at the University Hospital of Liège. Since 20 years or so, the dermatopathology laboratory with the contribution of the Mosan Study Group of Pigmented ... [more ▼]

Cutaneous melanoma is one of the research poles at the University Hospital of Liège. Since 20 years or so, the dermatopathology laboratory with the contribution of the Mosan Study Group of Pigmented Neoplasms have scrutenised the epidemiological evolution of this cancer. We have disclosed a sharp increase in the global incidence of melanoma, more particularly in women in the age of procreation. We have also contributed and innovated in terms of clinical diagnosis by introducing dermoscopy and initiating both the ULEV method and the cyanoacrylate skin surface stripping. In the field of dermatopathology we have developed an immunohistological panel allowing to fine tune the diagnosis and to define some histoprognostic criteria. For the checkup of the disease extension, the PET scan method has been particularly refined. [less ▲]

Detailed reference viewed: 43 (8 ULg)
Full Text
Peer Reviewed
See detailLe mélanome cutané sporadique au-delà de sa classification normative. Plaidoyer prenant en compte son particularisme évolutif
Pierard, Gérald ULg; Pierard-Franchimont, Claudine ULg

in Revue Médicale de Liège (2015), 70(5-6), 277-281

For aeons, cutaneous sporadic melanoma, exhibiting either a slow or rapid growth rate, is identified using a set of well defined histopathological criteria. Such diagnostic step is greatly appreciated ... [more ▼]

For aeons, cutaneous sporadic melanoma, exhibiting either a slow or rapid growth rate, is identified using a set of well defined histopathological criteria. Such diagnostic step is greatly appreciated, and it brings a rough estimate of the probable evolution of the cancer. Some additional assessments try to improve the progressive prognosis of cutaneous melanoma. In this scope, fractals and spectral analyses expect to better perceive the individual progressive characteristics of each tumor. The extent in the tumoral germinative compartment and the peritumoral microvascular network are explored and should in a near future make clear the progressive potential of cutaneous melanoma. The possible tumoral regression and the immune reaction should be better perceived. [less ▲]

Detailed reference viewed: 35 (7 ULg)
Full Text
Peer Reviewed
See detailLe melanome cutane: innovations conceptuelles et therapeutiques, fruit de la recherche translationnelle.
Pierard, Gérald ULg; Quatresooz, Pascale ULg; Rorive, Andrée ULg et al

in Revue Médicale de Liège (2008), 63(10), 579-84

The scientific information about melanoma is on the rise. It has a direct impact on the diagnostic acuteness and on the therapeutic management. The most recent aspects of the utmost importance are ... [more ▼]

The scientific information about melanoma is on the rise. It has a direct impact on the diagnostic acuteness and on the therapeutic management. The most recent aspects of the utmost importance are presented. The concept of the duality between fast-growing (high malignancy) and slow-growing (reduced malignancy) melanoma is stressed. A new international multicentric approach using adjuvant therapy for stage III melanomas involves the clinical oncology department of the CHU of Liege. It concerns a targeted immunotherapy directed to the Mage A3 protein. [less ▲]

Detailed reference viewed: 133 (9 ULg)
Full Text
Peer Reviewed
See detailLe melanome cutane: une seule maladie?
PIERARD, Gérald ULg; Franchimont, Claudine ULg; Hermanns-Lê, Trinh ULg et al

in Revue Médicale de Liège (2012), 67(9), 458-60

For the media and the public at large, malignant melanoma is the most dreadful cancer of the skin. This statement is obvious. However, some nuances merit to be considered. The clinical presentations ... [more ▼]

For the media and the public at large, malignant melanoma is the most dreadful cancer of the skin. This statement is obvious. However, some nuances merit to be considered. The clinical presentations, histopathology and molecular genetics point to the fact that malignant melanoma is not a single monolithic pathological condition. Different types of melanomas are distinguished based on distinct origins and contrasted prognoses. The management and information for the patient should be handled individually. [less ▲]

Detailed reference viewed: 39 (11 ULg)